(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial in progress (NCT04689828). This study examines the role of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in taxane-naïve patients with mCRPC. 177Lu-PSMA-617 is a high-affinity prostate-specific membrane antigen (PSMA)-targeted radioligand therapy that delivers β-particle radiation to cell expressing PSMA and the surrounding microenvironment. Among patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with ≥ 1 androgen receptor pathway inhibitor (ARPI) and 1–2 taxanes, the phase III VISION trial demonstrated that 177Lu-PSMA-617 significantly prolonged radiographic progression-free survival (rPFS) and overall survival. In the PSMAfore trial, Dr. Morris and colleagues are investigating the effect of 177Lu-PSMA-617 on rPFS in taxane-naïve patients with mCRPC treated with either 177Lu-PSMA-617 or a change in ARPI.